News
CMMI considers weight loss drug coverage pilot as Trump IVF pledge slips: reports
The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, while the Trump administration appears to be backing away from a campaig | The Trump administration has not adamantly pursued policies in support of in vitro fertilization coverage,
Money Talks News on MSN6h
Medicare to Slash Prices on Ozempic, 14 Other Drugs — but Not Until 2027Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.
GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday. The ...
Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback